{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:18:23Z","timestamp":1792498703238,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00210-025-04215-7","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:51:49Z","timestamp":1745902309000},"page":"14425-14439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8817-2242","authenticated-orcid":false,"given":"Randa Hisham","family":"Aljorani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-383X","authenticated-orcid":false,"given":"Adeeb Ahmed","family":"Al-Zubaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5240-2949","authenticated-orcid":false,"given":"Nibrass Taher","family":"Abdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"4215_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00210-017-1343-x","volume":"390","author":"NT Abdali","year":"2017","unstructured":"Abdali NT, Yaseen AH, Said E, Ibrahim TM (2017) Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage. N-S Arch Pharmacol 390:409\u2013422","journal-title":"N-S Arch Pharmacol"},{"issue":"11","key":"4215_CR2","doi-asserted-by":"publisher","first-page":"e23450","DOI":"10.1002\/jbt.23450","volume":"37","author":"MM Abdel-Fattah","year":"2023","unstructured":"Abdel-Fattah MM, Abo-El Fetoh ME, Afify H, Ramadan LA, Mohamed WR (2023) Probenecid ameliorates testosterone-induced benign prostatic hyperplasia: implications of PGE-2 on ADAM-17\/EGFR\/ERK1\/2 signaling cascade. J Biochem Mol Toxico 37(11):e23450","journal-title":"J Biochem Mol Toxico"},{"key":"4215_CR3","first-page":"12","volume":"3","author":"AF Abed Mansoor","year":"2022","unstructured":"Abed Mansoor AF, Abu Raghif AR (2022) Attenuated effects of rivastigmine in induced cytokine storm in mice. J Emerg Med 3:12","journal-title":"J Emerg Med"},{"key":"4215_CR4","doi-asserted-by":"publisher","first-page":"118414","DOI":"10.1016\/j.lfs.2020.118414","volume":"260","author":"AM Abo-Youssef","year":"2020","unstructured":"Abo-Youssef AM, Afify H, Azouz AA, Abdel-Rahman HM, Abdel-Naim AB, Allam S (2020) Febuxostat attenuates testosterone-induced benign prostatic hyperplasia in rats via inhibiting JAK\/STAT axis. Life Sci 260:118414","journal-title":"Life Sci"},{"key":"4215_CR5","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.taap.2020.115122","volume":"402","author":"H Afify","year":"2020","unstructured":"Afify H, Abo-Youssef AM, Abdel-Rahman HM, Allam S, Azouz AA (2020) The modulatory effects of cinnamaldehyde on uric acid level and IL-6\/JAK1\/STAT3 signaling as a promising therapeutic strategy against benign prostatic hyperplasia. Toxicol Appl Pharmacol 402:115122","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"4215_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.25130\/tjphs.2022.16.1.2.9.18","volume":"16","author":"NH Ahmed","year":"2022","unstructured":"Ahmed NH, Al-Zubaidy AA, Qasim BJ (2022) Effect of tadalafil in comparison with clobetasol ointment in induced psoriasis in mice male. Tikrit J Pharm Sci 16(1):9\u201318","journal-title":"Tikrit J Pharm Sci"},{"issue":"1","key":"4215_CR7","doi-asserted-by":"publisher","first-page":"14801","DOI":"10.1038\/s41598-023-41781-3","volume":"13","author":"R Ahmed","year":"2023","unstructured":"Ahmed R, Hamdy O, Awad RM (2023) Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network. Sci Rep 13(1):14801","journal-title":"Sci Rep"},{"key":"4215_CR8","unstructured":"Al-Mukhtar EJ, Al-Zubaidy AA, Al-Khuzaee LM (2013) Finasteride (plus oral contraceptive pill) vs metformin in treatment of polycystic ovary syndrome-related infertility: a prospective randomized trial. Iraqi J Med Sci 11(1)"},{"key":"4215_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","volume":"12","author":"PA Baeuerle","year":"1994","unstructured":"Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141\u2013179","journal-title":"Annu Rev Immunol"},{"key":"4215_CR10","doi-asserted-by":"publisher","first-page":"554078","DOI":"10.3389\/fendo.2021.554078","volume":"12","author":"R Cannarella","year":"2021","unstructured":"Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE (2021) Endocrinology of the aging prostate: current concepts. Front Endocrinol 12:554078","journal-title":"Front Endocrinol"},{"issue":"1","key":"4215_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2(1):1\u20135","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"4215_CR12","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.3390\/molecules26237141","volume":"26","author":"E Csik\u00f3s","year":"2021","unstructured":"Csik\u00f3s E, Horv\u00e1th A, \u00c1cs K, Papp N, Bal\u00e1zs VL (2021) Dolenc MS, Kenda M, Ko\u010devar Glava\u010d N, Nagy M, Protti M, Mercolini L, Treatment of benign prostatic hyperplasia by natural drugs. Molecules 26(23):7141","journal-title":"Molecules"},{"key":"4215_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clnesp.2019.07.015","volume":"33","author":"K Das","year":"2019","unstructured":"Das K, Buchholz N (2019) Benign prostate hyperplasia and nutrition. Clin Nutr ESPEN 33:5\u201311","journal-title":"Clin Nutr ESPEN"},{"issue":"11","key":"4215_CR14","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00345-020-03106-1","volume":"38","author":"C De Nunzio","year":"2020","unstructured":"De Nunzio C, Salonia A, Gacci M, Ficarra V (2020) Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol 38(11):2771\u20132779","journal-title":"World J Urol"},{"issue":"4","key":"4215_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","volume":"127","author":"CM Devlin","year":"2021","unstructured":"Devlin CM, Simms MS, Maitland NJ (2021) Benign prostatic hyperplasia\u2013what do we know? BJU Int 127(4):389\u2013399","journal-title":"BJU Int"},{"key":"4215_CR16","doi-asserted-by":"publisher","first-page":"614897","DOI":"10.3389\/fphar.2020.614897","volume":"11","author":"BG Eid","year":"2020","unstructured":"Eid BG, Abdel-Naim AB (2020) Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2\/HO-1\/NF\u03baB axis. Front Pharmacol 11:614897","journal-title":"Front Pharmacol"},{"key":"4215_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fphar.2017.00234","volume":"8","author":"C Eleazu","year":"2017","unstructured":"Eleazu C, Eleazu K, Kalu W (2017) Management of benign prostatic hyperplasia: could dietary polyphenols be an alternative to existing therapies? Front Pharmacol 8:234","journal-title":"Front Pharmacol"},{"issue":"6","key":"4215_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/antiox11061149","volume":"11","author":"DM Elsherbini","year":"2022","unstructured":"Elsherbini DM, Almohaimeed HM, El-Sherbiny M, Mohammedsaleh ZM, Elsherbiny NM, Gabr SA, Ebrahim HA (2022) Origanum majorana L. extract attenuated benign prostatic hyperplasia in rat model: effect on oxidative stress, apoptosis, and proliferation. Antioxidants 11(6):1149","journal-title":"Antioxidants"},{"key":"4215_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108082","volume":"100","author":"M El-Sherbiny","year":"2021","unstructured":"El-Sherbiny M, El-Shafey M, El-Agawy MS, Mohamed AS, Eisa NH, Elsherbiny NM (2021) Diacerein ameliorates testosterone-induced benign prostatic hyperplasia in rats: effect on oxidative stress, inflammation and apoptosis. Int Immunopharmacol 100:108082","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4215_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ucl.2021.07.007","volume":"49","author":"D Elterman","year":"2022","unstructured":"Elterman D, Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B (2022) New technologies for treatment of benign prostatic hyperplasia. Urol Clin North Am 49(1):11\u201322","journal-title":"Urol Clin North Am"},{"issue":"1","key":"4215_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ilar.47.1.5","volume":"47","author":"MF Festing","year":"2006","unstructured":"Festing MF (2006) Design and statistical methods in studies using animal models of development. ILAR J 47(1):5\u201314","journal-title":"ILAR J"},{"key":"4215_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-014-0463-9","volume":"15","author":"V Ficarra","year":"2014","unstructured":"Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 15:1\u20136","journal-title":"Curr Urol Rep"},{"key":"4215_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1464-410X.2006.06104.x","volume":"97","author":"F Giuliano","year":"2006","unstructured":"Giuliano F (2006) Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97:34\u201338","journal-title":"BJU Int"},{"key":"4215_CR24","first-page":"1","volume":"24","author":"AM Hasan","year":"2024","unstructured":"Hasan AM, Gatea FK (2024) Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice. N-S Arch Pharmacol 24:1\u20134","journal-title":"N-S Arch Pharmacol"},{"issue":"10","key":"4215_CR25","first-page":"6433","volume":"11","author":"P He","year":"2019","unstructured":"He P, Guo Y, Wang J, Yan L, Feng A (2019) Protection of ripasudil, a Rho kinase inhibitor, in lipopolysaccharides-induced acute pneumonia in mice. Am J Transl Res 11(10):6433","journal-title":"Am J Transl Res"},{"issue":"15","key":"4215_CR26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/pros.23063","volume":"75","author":"F Holmstr\u00f6m","year":"2015","unstructured":"Holmstr\u00f6m F, Shimizu S, Shimizu T, Higashi Y, Martin DT, Honda M, Saito M (2015) Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. Prostate 75(15):1774\u20131782","journal-title":"Prostate"},{"key":"4215_CR27","doi-asserted-by":"crossref","unstructured":"Hu WY, Afradiasbagharani P, Lu R, Liu L, Birch LA, Prins GS (2021) Morphometric analysis of rat prostate development: roles of MEK\/ERK and Rho signaling pathways in prostatic morphogenesis. Biomolecules 11(12):1829","DOI":"10.3390\/biom11121829"},{"issue":"1","key":"4215_CR28","doi-asserted-by":"publisher","first-page":"11131","DOI":"10.1038\/s41598-024-61269-y","volume":"14","author":"ZA Hussein","year":"2024","unstructured":"Hussein ZA, Abu-Raghif AR, Tahseen NJ, Rashed KA, Shaker NS, Fawzi HA (2024) Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-\u03b3\/NLRP3\/NF-\u03baB and TGF-\u03b21\/Smad2\/3 pathways. Sci Rep 14(1):11131","journal-title":"Sci Rep"},{"issue":"3","key":"4215_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/nu15030682","volume":"15","author":"YJ Jang","year":"2023","unstructured":"Jang YJ, Jung HY, Myeong JY, Song KH, Kwon J, Kim D, Park JI (2023) Effects of alginate oligosaccharide on testosterone-induced benign prostatic hyperplasia in orchiectomized rats. Nutrients 15(3):682","journal-title":"Nutrients"},{"issue":"2","key":"4215_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4103\/1008-682X.140966","volume":"17","author":"TR Jarvis","year":"2015","unstructured":"Jarvis TR, Chughtai B, Kaplan SA (2015) Testosterone and benign prostatic hyperplasia. Asian J Androl 17(2):212\u2013216","journal-title":"Asian J Androl"},{"issue":"1\u20133","key":"4215_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejphar.2013.05.041","volume":"714","author":"YJ Jeon","year":"2013","unstructured":"Jeon YJ, Kim BH, Kim S, Oh I, Lee S, Shin J, Kim TY (2013) Rhododendrin ameliorates skin inflammation through inhibition of NF-\u03baB, MAPK, and PI3K\/Akt signaling. Eur J Pharmacol 714(1\u20133):7\u201314","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4215_CR32","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.18632\/aging.102731","volume":"12","author":"BR Jin","year":"2020","unstructured":"Jin BR, An HJ (2020) Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis. Aging (Albany NY) 12(3):2142","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"4215_CR33","doi-asserted-by":"publisher","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, Tanihara H (2016) Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci Rep 6(1):19640","journal-title":"Sci Rep"},{"key":"4215_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13273-018-0023-3","volume":"14","author":"J Kang","year":"2018","unstructured":"Kang J, Lee GH, Jung Y, Youn DH, Lim S, Park J, Um JY (2018) Igongsan reduces testosterone-induced benign prostate hyperplasia by regulating 5\u03b1-reductase in rats. Mol Cell Toxicol 14:211\u2013220","journal-title":"Mol Cell Toxicol"},{"issue":"1","key":"4215_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","volume":"67","author":"EH Kim","year":"2016","unstructured":"Kim EH, Larson JA, Andriole GL (2016) Management of benign prostatic hyperplasia. Annu Rev Med 67(1):137\u2013151","journal-title":"Annu Rev Med"},{"issue":"3","key":"4215_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.juro.2012.08.220","volume":"189","author":"M Lam","year":"2013","unstructured":"Lam M, Kerr KP, Exintaris B (2013) Involvement of Rho-kinase signaling pathways in nerve evoked and spontaneous contractions of the Guinea pig prostate. J Urol 189(3):1147\u20131154","journal-title":"J Urol"},{"issue":"2","key":"4215_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan RC (2019) Benign prostatic hyperplasia. Prim Care Clin Office Pract 46(2):223\u2013232","journal-title":"Prim Care Clin Office Pract"},{"issue":"1","key":"4215_CR38","first-page":"9","volume":"8","author":"F Li","year":"2020","unstructured":"Li F, Pascal LE, Wang K, Zhou Y, Balasubramani GK, O\u2019Malley KJ, Dhir R, He K, Stolz D, DeFranco DB, Yoshimura N (2020) Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function. Am J Clin Exp Urol 8(1):9","journal-title":"Am J Clin Exp Urol"},{"issue":"4","key":"4215_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"issue":"5","key":"4215_CR40","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000496289","volume":"65","author":"S Madersbacher","year":"2019","unstructured":"Madersbacher S, Sampson N, Culig Z (2019) Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontol 65(5):458\u2013464","journal-title":"Gerontol"},{"issue":"2","key":"4215_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/molecules26020450","volume":"26","author":"K Mitsunari","year":"2021","unstructured":"Mitsunari K, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Harada J, Kondo T, Matsuda T, Ohba K, Sakai H (2021) Pharmacological effects and potential clinical usefulness of polyphenols in benign prostatic hyperplasia. Molecules 26(2):450","journal-title":"Molecules"},{"issue":"6","key":"4215_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41419-022-04995-3","volume":"13","author":"WY Park","year":"2022","unstructured":"Park WY, Song G, Park JY, Ahn KS, Kwak HJ, Park J, Lee JH, Um JY (2022) Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3. Cell Death Dis 13(6):554","journal-title":"Cell Death Dis"},{"issue":"2","key":"4215_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.sxmr.2018.10.006","volume":"7","author":"G Rastrelli","year":"2019","unstructured":"Rastrelli G, Vignozzi L, Corona G, Maggi M (2019) Testosterone and benign prostatic hyperplasia. Sex Med Rev 7(2):259\u2013271","journal-title":"Sex Med Rev"},{"key":"4215_CR44","doi-asserted-by":"publisher","first-page":"112779","DOI":"10.1016\/j.jep.2020.112779","volume":"255","author":"J Rho","year":"2020","unstructured":"Rho J, Seo CS, Park HS, Jeong HY, Moon OS, Seo YW, Son HY, Won YS, Kwun HJ (2020) Asteris Radix et Rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation. J Ethnopharmacol 255:112779","journal-title":"J Ethnopharmacol"},{"key":"4215_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11010-011-0936-9","volume":"358","author":"M Saito","year":"2011","unstructured":"Saito M, Ohmasa F, Shomori K, Dimitriadis F, Ohiwa H, Shimizu S, Tsounapi P, Kinoshita Y, Satoh K (2011) Rhos and Rho kinases in the rat prostate: their possible functional roles and distributions. Mol Cell Biochem 358:207\u2013213","journal-title":"Mol Cell Biochem"},{"key":"4215_CR46","doi-asserted-by":"crossref","unstructured":"Sasidharan S, Srinivasakumar KP, Poddar S, Bhaumik A, Das SK (2022) Benign prostatic hyperplasia (BPH): a comprehensive analysis of the malaise and summarizing possible management options through phytotherapeutic agents. Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal) 17(2)","DOI":"10.21109\/kesmas.v17i2.5887"},{"key":"4215_CR47","doi-asserted-by":"crossref","unstructured":"Shah A, Shah AA, K N, Lobo R, (2021) Mechanistic targets for BPH and prostate cancer\u2013a review. Rev Environ Health 36(2):261\u2013270","DOI":"10.1515\/reveh-2020-0051"},{"issue":"1","key":"4215_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10020-023-00734-2","volume":"29","author":"S Shan","year":"2023","unstructured":"Shan S, Su M, Li Y, Wang Z, Liu D, Zhou Y, Fu X, Yang S, Zhang J, Qiu J, Liu H (2023) Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-\u03b2-catenin signaling axis and static & dynamic dual roles. J Mol Med 29(1):139","journal-title":"J Mol Med"},{"key":"4215_CR49","first-page":"7958316","volume":"1","author":"Y Tong","year":"2020","unstructured":"Tong Y, Zhou RY (2020) Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflamm 1:7958316","journal-title":"Mediators of Inflamm"},{"issue":"5","key":"4215_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/13685538.2018.1470233","volume":"23","author":"N Torrealba","year":"2020","unstructured":"Torrealba N, Rodr\u00edguez-Berriguete G, Vera R, Fraile B, Olmedilla G, Mart\u00ednez-Onsurbe P, S\u00e1nchez-Chapado M, Paniagua R, Royuela M (2020) Homeostasis: apoptosis and cell cycle in normal and pathological prostate. Aging Male 23(5):335\u2013345","journal-title":"Aging Male"},{"key":"4215_CR51","doi-asserted-by":"crossref","unstructured":"Tsounapi P, Saito M, Kitatani K, Dimitriadis F, Ohmasa F, Shimizu S, ... & Satoh K (2012) Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats. Eur J Pharmacol 691(1\u20133):182\u2013189","DOI":"10.1016\/j.ejphar.2012.07.016"},{"issue":"12","key":"4215_CR52","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1167\/iovs.17-22679","volume":"58","author":"T Uchida","year":"2017","unstructured":"Uchida T, Honjo M, Yamagishi R, Aihara M (2017) The anti-inflammatory effect of ripasudil (K-115), a rho kinase (ROCK) inhibitor, on endotoxin-induced uveitis in rats. Invest Ophthalmol vis Sci 58(12):5584\u20135593","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"5","key":"4215_CR53","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1476-5381.2011.01332.x","volume":"163","author":"S Ventura","year":"2011","unstructured":"Ventura S, Oliver VL, White CW, Xie JH, Haynes JM, Exintaris B (2011) Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol 163(5):891\u2013907","journal-title":"Br J Pharmacol"},{"issue":"3","key":"4215_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","volume":"7","author":"RE Vickman","year":"2020","unstructured":"Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW (2020) The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol 7(3):191\u2013202","journal-title":"Asian J Urol"},{"key":"4215_CR55","doi-asserted-by":"publisher","first-page":"113703","DOI":"10.1016\/j.jep.2020.113703","volume":"279","author":"S Wang","year":"2021","unstructured":"Wang S, Li Y, Li W, Zhang K, Yuan Z, Cai Y, Xu K, Zhou J, Du Z (2021) Curcuma oil ameliorates benign prostatic hyperplasia through suppression of the nuclear factor-kappa B signaling pathway in rats. J Ethnopharmacol 279:113703","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"4215_CR56","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4103\/1673-5374.335827","volume":"17","author":"Q Wang","year":"2022","unstructured":"Wang Q, Song LJ, Ding ZB, Chai Z, Yu JZ, Xiao BG, Ma CG (2022) Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Neural Regen Res 17(12):2623\u20132631","journal-title":"Neural Regen Res"},{"key":"4215_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jep.2014.09.025","volume":"157","author":"X Yang","year":"2014","unstructured":"Yang X, Yuan L, Xiong C, Yin C, Ruan J (2014) Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 157:105\u2013113","journal-title":"J Ethnopharmacol"},{"key":"4215_CR58","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.12659\/MSM.910184","volume":"24","author":"J Yang","year":"2018","unstructured":"Yang J, Ruan F, Zheng Z (2018) Ripasudil attenuates lipopolysaccharide (LPS)-mediated apoptosis and inflammation in pulmonary microvascular endothelial cells via ROCK2\/eNOS signaling. Med Sci Monit 24:3212","journal-title":"Med Sci Monit"},{"key":"4215_CR59","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fphar.2020.00658","volume":"11","author":"ZJ Yu","year":"2020","unstructured":"Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, Huang JB, Zeng T (2020) Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol 11:658","journal-title":"Front Pharmacol"},{"key":"4215_CR60","doi-asserted-by":"publisher","first-page":"5896136","DOI":"10.1155\/2021\/5896136","volume":"1","author":"MJ Zhao","year":"2021","unstructured":"Zhao MJ, Yuan S, Zi H, Gu JM, Fang C, Zeng XT (2021) Oxidative stress links aging-associated cardiovascular diseases and prostatic diseases. Oxid Med Cell Longev 1:5896136","journal-title":"Oxid Med Cell Longev"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04215-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:02:38Z","timestamp":1759986158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04215-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. It was approved by the \u201cResearch Ethics Committee at the College of Medicine, Al-Nahrain University\u201d following approval from the Institutional Review Board (IRB) committee (Animal ethical approval number: 202207175, date: 6\u2009th November 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}